December 9, 2013
FPMAJ Chairman Haruo Naito (right) The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) will basically accept the health ministry’s compromise proposal to “institutionalize” the premium for new drug development, in lieu of the industry’s long-standing plea to introduce it...read more